0001144204-17-044700.txt : 20170823 0001144204-17-044700.hdr.sgml : 20170823 20170823120934 ACCESSION NUMBER: 0001144204-17-044700 CONFORMED SUBMISSION TYPE: RW PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20170823 DATE AS OF CHANGE: 20170823 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Accelerated Pharma, Inc. CENTRAL INDEX KEY: 0001630970 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: RW SEC ACT: SEC FILE NUMBER: 333-214048 FILM NUMBER: 171046625 BUSINESS ADDRESS: STREET 1: 15W155 81ST STREET CITY: BURR RIDGE STATE: IL ZIP: 60527 BUSINESS PHONE: 773-517-0789 MAIL ADDRESS: STREET 1: 15W155 81ST STREET CITY: BURR RIDGE STATE: IL ZIP: 60527 RW 1 v473903_rw.htm RW

Accelerated Pharma, Inc.

36 Church Lane
Westport, Connecticut 06880

Application for Withdrawal of Registration Statement

August 23, 2017

U.S. Securities and Exchange Commission

Division of Corporation Finance

Washington, D.C. 20549

Registration Statement on Form S-1

Filed on July 12, 2017

File No. 333-214048

Ladies and Gentlemen:

Pursuant to Rule 477 under the Securities Act of 1933, as amended (the “Act”), Accelerated Pharma, Inc.(the “Company”) hereby requests the withdrawal of the Company’s registration statement on Form S-1, the most recent amendment of which was filed with the United States Securities and Exchange Commission (the “SEC”) on July 12, 2017. The Company requests the withdrawal of the registration statement because the Company has decided not to proceed with this underwritten offering. The registration statement has not been declared effective and no shares of the Company’s common stock or other securities have been sold under the registration statement.

The Company requests that, in accordance with Rule 457(p) under the Act, all fees paid to the SEC in connection with the filing of the registration statement be credited for future use.

If you have any questions with respect to this matter, please call the Office of Richard Rubin, at 917-957-9092. Thank you for your assistance in this matter.

Respectfully submitted,

/s/: Michael Fonstein, PhD.

Michael Fonstein, CEO